In cholangiocarcinoma and lung cancer, we also observed a negative correlation with metabolic pathways, suggesting that similar functions predicted for PRRX1 in HCC may apply to other cancer types (Fig. S4). This evidence concerns the gene PRRX1 and lung carcinoma.